top of page

SOTIO to Present Translational Data of the IL-15 Superagonist SO-C101 at 2018 AACR Annual Meeting

April 10, 2018 Source: Press Release, Prague


SOTIO, a biotechnology company owned by the PPF Group, announces today presentation of a poster on SO-C101 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2018. The poster, titled “Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response,” will highlight preclinical and translational data evaluating SO-C101 (RLI-15). The AACR Annual Meeting will be held on April 14 – 18, 2018 in Chicago, Illinois.

The poster will be presented at poster session PO.IM02.07 - Immunomodulatory Agents and Interventions 1 on April 17, 2018 at 8:00 a.m. - 12:00 p.m. An abstract of the presentation is available on AACR website.

The preclinical data show several positive effects of SO-C101 in the induction of anti- tumor immunity, including the combination treatment of SO-C101 with an anti-PD1 antibody leading to a significant anti-tumor efficacy in a TRAMP-C2 prostate cancer mouse model with 70% of mice remaining tumor free after the treatment. The activity of clinical-grade SO-C101 was tested in vitro on human PBMCs and the superiority over IL-2 and IL-15 stimulatory capacity has been confirmed. Furthermore, SO-C101 induced lymphocyte activation and expansion in non-human primates at well tolerated doses.

About SO-C101

SO-C101 is developed in collaboration with Cytune Pharma, an affiliated company of SOTIO. SO-C101 (RLI-15) is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Rα. It is a novel immunotherapeutic approach with potential applications in a variety of oncology indications. In preclinical experiments, SO-C101 has been shown to stimulate and induce proliferation of immune effector cells, such as cytotoxic T cells and NK cells, but it does not stimulate the immune-inhibitory regulatory T cells. Based on the preclinical experiments, SO-C101 is more potent and better tolerated compared to the unmodified IL-15 or IL-2. SO-C101 and other products based on this platform allow for combinations with other immunotherapeutic

strategies including checkpoint inhibitors. SOTIO is planning to initiate a first in human study early in 2019.

22 views0 comments


bottom of page